EASTONBIOPHARMACEUTICALS(SH:688513)2021-04-15 16:00Financial Performance - Operating revenue for the period was CNY 221,248,014.12, representing a year-on-year growth of 25.42%[12] - Net profit attributable to shareholders was CNY 43,292,471.03, up 41.04% from the same period last year[12] - The net cash flow from operating activities was CNY 28,095,990.56, an increase of 41.49% year-on-year[12] - Basic and diluted earnings per share were both CNY 0.36, a 5.88% increase from the previous year[12] - Total revenue for Q1 2021 reached ¥221,248,014.12, a 25.4% increase from ¥176,410,215.89 in Q1 2020[47] - Operating profit for Q1 2021 was ¥46,894,554.16, up 39.0% from ¥33,723,445.41 in Q1 2020[47] - Net profit for Q1 2021 was ¥43,292,471.03, representing a 41.0% increase compared to ¥30,694,258.24 in Q1 2020[50] - The total comprehensive income for the first quarter of 2021 was ¥28,396,454.65, compared to ¥21,861,452.59 in the first quarter of 2020, representing an increase of approximately 29.3%[56] Research and Development - R&D investment accounted for 18.89% of operating revenue, an increase of 4.25 percentage points compared to the previous year[12] - Research and development expenses increased by 61.78% to ¥41,794,134.64 from ¥25,834,212.50, reflecting continued investment in ongoing projects[26] - Research and development expenses increased to ¥41,794,134.64 in Q1 2021, up 62.0% from ¥25,834,212.50 in Q1 2020[47] Cash Flow and Investments - Cash and cash equivalents decreased by 79.96% to ¥211,431,335.46 from ¥1,055,289,158.05 due to the use of idle funds for purchasing financial products[22] - Cash inflow from operating activities totaled ¥278,516,932.87, up from ¥223,440,668.39 in the same period last year, indicating a growth of about 24.7%[59] - The net cash flow from investment activities was -¥871,690,550.73, compared to -¥73,321,386.02 in the first quarter of 2020, showing a deeper cash outflow[59] - The company experienced a net decrease in cash and cash equivalents of ¥843,857,822.59 during the first quarter of 2021, compared to a decrease of ¥57,396,216.49 in the same period last year[62] Shareholder Information - The total number of shareholders at the end of the reporting period was 9,268[14] - The top shareholder, Wang Ying, held 34.89% of the shares, totaling 41,900,000 shares[14] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 2,556,132,835.15, an increase of 1.00% compared to the end of the previous year[12] - Total liabilities decreased from ¥435,609,899.90 to ¥417,233,414.10, a reduction of approximately 4.0%[36] - Total assets increased from ¥2,103,426,558.46 to ¥2,206,617,274.19, representing a growth of about 4.9%[41] - The company reported a total current asset of ¥961,690,630.23, up from ¥857,335,008.28, an increase of approximately 12.2%[40] - The total non-current assets slightly decreased from ¥1,246,091,550.18 to ¥1,244,926,643.96, a reduction of about 0.1%[40] Other Financial Metrics - The weighted average return on equity decreased by 2.27 percentage points to 2.04%[12] - Financial income increased significantly, with investment income rising by 159.84% to ¥3,628,468.37 from ¥1,396,409.14, mainly due to increased financial product returns[26] - The company reported a significant increase in special reserves by 648.16% to ¥415,184.96 from ¥55,493.89, reflecting the provision for special reserves during the period[26] - Long-term deferred expenses increased by 35.10% to ¥4,617,310.50 from ¥3,417,644.80, mainly due to increased renovation costs[26] - Contract liabilities decreased by 48.73% to ¥8,442,779.45 from ¥16,468,559.73, attributed to revenue recognition[26]